Cite
HARVARD Citation
von Moos, R. et al. (n.d.). 1703PIncidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of oncology. p. . [Online].